Drugs / Puumala DNA Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04333459 Comparator | Aug 2021 → Oct 2024 | Hantavirus hemorrhagic fever with renal syndrome, Puumala virus type | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Puumala DNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04333459 ↗ |
| Known as | pWRG/PUU-M(s2) | “Group 3 will be vaccinated with the PUUV DNA vaccine, pWRG/PUU-M(s2) at the 2 mg/vaccination dose.” NCT04333459 ↗ |
| Modality | Vaccine | “PUUV DNA vaccine” NCT04333459 ↗ |